ClinicalTrials.Veeva

Menu

Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia (FERTILAM)

U

University Hospital, Lille

Status

Completed

Conditions

Acute Myeloid Leukemia

Study type

Observational

Funder types

Other

Identifiers

NCT04679285
2020-A01513-36 (Other Identifier)
2020_12

Details and patient eligibility

About

Cryopreservation of ovarian cortex represents an option for fertility preservation in patients diagnosed with acute myeloid leukemia and requiring allogeneic stem cell transplantation.

This pilot study aims to evaluate the minimal residual disease on ovarian fragments harvested before allogeneic stem cell transplantation at the time of complete remission.

Enrollment

9 patients

Sex

Female

Ages

2 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient diagnosed with AML
  • At least one molecular marker identified at AML diagnosis
  • Patients who undergo ovarian tissue cryopreservation for fertility preservation in complete remission, before hematopoietic stem cell transplantation.

Exclusion criteria

  • Other diagnostic
  • No marker available at AML diagnosis
  • No bone marrow/ovarian fragment available at the time of complete remission

Trial contacts and locations

1

Loading...

Central trial contact

Laurène Fenwarth, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems